<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792216</url>
  </required_header>
  <id_info>
    <org_study_id>20-1033</org_study_id>
    <nct_id>NCT04792216</nct_id>
  </id_info>
  <brief_title>Salmon Intake and Gut Health in Adults</brief_title>
  <official_title>Salmon Intake and Gut Health in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this project is to determine the interplay of salmon as a whole food&#xD;
      and its bioactive compound astaxanthin on gut microbiome, fecal metabolome, and inflammation&#xD;
      in obese prediabetic individuals. Our central hypothesis is that dietary bioactive&#xD;
      astaxanthin in the form of whole food salmon will effectively reduce inflammation in obese&#xD;
      prediabetic individuals, and favorably change the gut microbiota composition and diversity.&#xD;
      The investigators anticipate that these changes will result in improved metabolic outcomes in&#xD;
      obesity and type 2 diabetes.&#xD;
&#xD;
      The two primary aims include:&#xD;
&#xD;
      Aim 1: Assess the anti-inflammatory effect of the salmon dietary intervention and the&#xD;
      underlying mechanisms on the change in plasma levels of inflammatory cytokines important for&#xD;
      the host immune response.&#xD;
&#xD;
      Aim 2: Identify whether the relationship between salmon consumption and decreased&#xD;
      inflammation is mediated by the gut microbiome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this project is to determine whether increased intake of salmon as a whole food&#xD;
      and its bioactive compound astaxanthin has a causal impact on preventing inflammation by&#xD;
      promoting human gut microbiome homeostasis. Findings from this study will provide new&#xD;
      insights into maintenance of gut microbiome and will inform effective dietary recommendations&#xD;
      and interventions, thereby reducing inflammation-associated diseases in humans.&#xD;
&#xD;
      Aim: Evaluate the anti-inflammatory properties of astaxanthin-enriched salmon via&#xD;
      re-balancing of human gut microbiome in obese prediabetic human subjects.&#xD;
&#xD;
      The investigators will use a randomized, double-blind, crossover feeding study with 15 obese&#xD;
      prediabetic males and 15 obese prediabetic females (n=30) . Participants will consume two&#xD;
      servings (3 oz per serving) of wild salmon (intervention 1) and farmed salmon (intervention&#xD;
      2) daily in random orders. Each intervention is 4 weeks long and the washout duration between&#xD;
      the two interventions is 5 weeks. Primary outcomes will be determined by measuring the&#xD;
      inflammatory response and gut microbiota composition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood biomarkers/inflammatory cytokines</measure>
    <time_frame>Over 32 weeks</time_frame>
    <description>Blood from patients will be processed via centrifugation to archive plasma. A panel of 48 factors from Bio-Rad (Bio-Plex Pro™ Human Cytokine Screening Panel, 48-Plex #12007283) will be measured in plasma by Bio-Rad Bio-Plex analyzer. Five primary biomarkers (IL-1β, IL-6, IL-10, TNF-α, and MCP-1) will be confirmed by traditional ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut Microbiome</measure>
    <time_frame>Over 32 weeks</time_frame>
    <description>Gut microbiota structure by 16S sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal metabolomics</measure>
    <time_frame>Over 32 weeks</time_frame>
    <description>Small molecules will be extracted using MTBE-based liquid:liquid extraction which results in lipid and aqueous fractions. Compounds will be &quot;extracted&quot; using commercial software (Mass Hunter, Agilent), quantitated using peak volumes and processed using Mass Profiler Professional (MPP, Agilent) to determine normalized compound intensities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine Analysis</measure>
    <time_frame>Over 32 weeks</time_frame>
    <description>Urine samples will be collected for future metabolomics analysis. This analysis will generate a metabolomics profile in biospecimens, which will help us identify potential signatures related to salmon intake</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gut Microbiome</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Wild Salmon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wild salmon fillets in a raw form</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Farmed Salmon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Farmed salmon fillets in a raw form</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Wild Salmon</intervention_name>
    <description>Wild salmon fillets</description>
    <arm_group_label>Wild Salmon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Farmed Salmon</intervention_name>
    <description>Farm salmon fillets</description>
    <arm_group_label>Farmed Salmon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and non-pregnant, non-lactating pre-menopausal females&#xD;
&#xD;
          -  BMI 30-40 kg/m2&#xD;
&#xD;
          -  Fasting blood glucose (without blood glucose-lowering drug) between 100-125 mg/dL&#xD;
&#xD;
          -  Plasma total cholesterol ≤ 250 mg/dL, plasma triglyceride level ≤ 250 mg/Dl&#xD;
&#xD;
          -  Age 30-50 years&#xD;
&#xD;
          -  Weight stable over the last 3 months (&lt; 2% body weight change)&#xD;
&#xD;
          -  Sedentary and stable physical activity regimen 3 months prior (≤3 h/wk of moderate or&#xD;
             high intensity exercise, resistance or aerobic training)&#xD;
&#xD;
          -  Medication use stable for 6 months prior, and not include anti-inflammatory drugs&#xD;
             (e.g. ibuprofen, aspirin)&#xD;
&#xD;
          -  Not taking a carotenoid-containing or metabolism-altering supplement for the last 1&#xD;
             month, or have autoimmune diseases, and other malabsorptive disorders (including&#xD;
             Crohn's, ileus or ulcerative colitis), liver or kidney insufficiency, allergies to&#xD;
             tomatoes&#xD;
&#xD;
          -  No current special diets or nutrient supplements, pre- or probiotics (~3 months)&#xD;
&#xD;
          -  No tobacco smoking&#xD;
&#xD;
          -  Limited consumption of alcoholic beverages ≤ 1/d&#xD;
&#xD;
          -  No frequent habitual consumption of salmon or other astaxanthin-rich foods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, lactating, or menopausal females&#xD;
&#xD;
          -  BMI &lt; 30 or &gt;40 kg/m2&#xD;
&#xD;
          -  Fasting blood glucose &lt;100 or &gt;125 mg/dL; or taking blood glucose lowering medication&#xD;
&#xD;
          -  Plasma total cholesterol &gt;250 mg/dL, plasma triglyceride level &gt;250 mg/Dl&#xD;
&#xD;
          -  Age &lt;30 or &gt;50 years&#xD;
&#xD;
          -  2% body weight change over the last 3 months&#xD;
&#xD;
          -  &gt;3 h/wk of moderate or high intensity exercise, resistance or aerobic training for the&#xD;
             3 months prior&#xD;
&#xD;
          -  Changing medications in the past 6 months&#xD;
&#xD;
          -  Taking anti-inflammatory drugs (e.g. ibuprofen, aspirin), carotenoid-containing or&#xD;
             metabolism-altering supplements (for the last 1 month), or have autoimmune diseases,&#xD;
             and other malabsorptive disorders (including Crohn's, ileus or ulcerative colitis),&#xD;
             liver or kidney insufficiency, or allergies to tomatoes&#xD;
&#xD;
          -  Currently on a special diet or taking nutrient supplements, pre- or probiotics (~3&#xD;
             months)&#xD;
&#xD;
          -  Tobacco smoking&#xD;
&#xD;
          -  &gt;1/d consumption of alcoholic beverages&#xD;
&#xD;
          -  Frequent habitual consumption of salmon or other astaxanthin-rich foods.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Minghua Tang, PhD</last_name>
    <phone>303-724-3248</phone>
    <email>minghua.tang@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minghua Tang, PhD</last_name>
      <phone>303-724-3248</phone>
      <email>minghua.tang@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Minghua Tang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

